The potential impact of the hypovitaminosis D on metabolic complications in obese adolescents - Preliminary results by Wójcik, Małgorzata et al.
Annals of Agricultural and Environmental Medicine 2017, Vol 24, No 4, 636–639
www.aaem.pl ORIGINAL ARTICLE 
The potential impact of the hypovitaminosis D 
on metabolic complications in obese 
adolescents – Preliminary results
Malgorzata Wojcik1, Dominika Janus1, Anna Kalicka-Kasperczyk1, Krystyna Sztefko2, 
Jerzy B. Starzyk1
1 Department of Pediatric and Adolescent Endocrinology, Chair of Pediatrics, Institute of Pediatrics, Jagiellonian 
University Medical College, Krakow, Poland  
2 Department of Clinical Biochemistry, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland
Wojcik M, Janus D, Kalicka-Kasperczyk A, Sztefko K, Starzyk J B. The potential impact of the hypovitaminosis D on metabolic complications 
in obese adolescents – Preliminary results. Ann Agric Environ Med. 2017; 24(4): 636–639. doi: 10.5604/12321966.1230676
Abstract
Introduction and objective. Vitamin D deficiency is common in obesity; however, its contribution in the development 
of metabolic complications remains uncertain. The aim of the study was to examine the relationships between vitamin D 
status and metabolic complications.  
Materials and method. The results of blood pressure measurements, biochemical tests and ultrasound of the liver were 
compared in both groups. The study was conducted at the Children’s University Hospital in Krakow, Poland. 30 obese 
adolescents (mean 13.23y.o.); 18 with 25OHD levels <20ng/mL, 12 with 25OHD>20 ng/mL.  
Results. The vitamin D deficient group presented with significantly higher values of the diastolic blood pressure 
(125.9vs.115mmHg), uric acid level (384.7vs.301.5umol/L) and lower phosphorus level (1.4vs.1.65mmol/L), higher prevalence 
of arterial hypertension (44vs.8.3%), and liver steatosis (25vs.8.3%); lower, but not significantly, levels of fibroblast growth 
factor 23 and fibroblast growth factor 19.  
Conclusions. Hypovitaminosis D in obese adolescents is associated with higher prevalence of arterial hypertension, liver 
steatosis, elevated serum uric acid and low phosphorus levels. The potential contribution of the fibroblast growth factor 
23 and fibroblast growth factor 19 in these complications development needs further investigation.
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INTRODUCTION
The global escalation of childhood obesity is a major public 
health issue, as excessive adiposity is the leading cause of 
metabolic and cardiovascular disease and their related 
mortality in adulthood. The main causes of this increase 
in cardiometabolic risk are a decrease in insulin sensitivity 
and compensatory hyperinsulinemia [1, 2, 3, 4]. A strong 
association between insulin resistance and an excess of fat 
tissue has been recognized for decades, but some details 
of its origin remain unclear to date. Undoubtedly there 
is a strong correlation between genetic background and 
environmental factors. Since it is not yet possible to modify 
the genetic background, it is essential to identify modifiable 
environmental factors. One of the most discussed in literature 
possible contributors of the obesity itself and its complications 
remains hypovitaminosis D. Many studies confirmed a 
high prevalence of vitamin D deficiency in obese patients, 
since both conditions are often associated. Approximately 
60%  of children and adolescents are overweight or obese 
in comparison to 20% of those who are non-obese subjects 
[1, 2, 3, 4]. However, an inverse correlation between body 
mass index (BMI), fat tissue content and vitamin D levels 
had been proved in many studies, and a recently published 
metaanalysis of 21 adult cohorts (up to 42,024 participants) 
revealed  that higher a BMI leads to a lower vitamin D 
level. However, low vitamin D level does not contribute 
to an increase in the BMI [3]. These results confirm that 
hypovitaminosis D is rather a consequence, not a cause of 
obesity. From this point of view, low vitamin D may not be 
considered as an isolated condition, but rather the potential 
indicator of the risk of other metabolic complications in 
obese patients. Moreover, since puberty is a critical life-stage 
period characterized by rapid growth and development, 
the deficiency of vitamin D may be relative and difficult to 
diagnose, because there are no specific reference values and 
cut-off points for vitamin D level in adolescents. Recent 
studies had shown, that hypovitaminosis D might be not 
only one of the many obesity complications, but may be 
also a potential trigger factor of the consecutive metabolic 
disturbances. It had been shown, that low vitamin D level 
may be involved in the activation of a pro-inflammatory, 
pro-diabetic and atherogenic pathways in obese children [2].
The presented study is an attempt to compare selected 
parameters of the metabolic assessment in obese patients 
with hypovitaminosis D and obese with normal 25OHD 
levels. The study is also the first attempt to assess a possible 
relationship between FGF23, FGF19 and vitamin D status 
in obese adolescents.
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OBJECTIVE
The aim of the study is to determine the possible relationship 
between hypovitaminosis D and specific metabolic 
consequences of obesity (lipid disorders, non-alcoholic 
liver steatosis and arterial hypertension) in adolescents. 
Additionally, determination of a possible relationship 
between FGF23, FGF19 and vitamin D status in obese 
adolescents was investigated.
MATERIALS AND NETHOD
The study included 30 obese adolescents (14 male and 16 
female) at the age of pubertly (mean age: 13.23 years, 95%CI 
12.64–13.8).
Body weight and height were measured to the nearest 0.1 kg 
and 0.1 cm, respectively, using a stadiometer (Harpenden, 
UK) and a balance scale. As the standard of references for 
normal BMI SDS, values from the local population were used. 
Pubertal development was assessed according to the Tanner 
scale – Tanner stage IV or V.
Systolic (SBP) and diastolic (DBP) blood pressure were 
measured 3 times, every 3 minutes, using a pneumatic 
sphygmomanometer. Mean values were counted from obtained 
measures. Arterial hypertension (HA) was defined as mean 
SBP and/or DBP over 95th percentile for age, height and gender.
Fasting levels of 25OHD were measured by high-
performance liquid chromatography. Hypovitaminosis D 
was defined as 25OHD < 20 ng/mL (50 nmol/L). Fasting 
concentration levels of glucose, total cholesterol LDL 
cholesterol (LDLc); HDL cholesterol concentration (HDLc), 
triglycerides (Tgl), uric acid (UA), alanine aminotransferase 
(ALT), asparginian aminotransferase (AST), gamma-
glutamylo transferase (GGT), calcium and phosphorus, were 
estimated in the fasting blood sample by the dry chemistry 
method with a Vitros 5.1.FF machine. Insulin concentrations 
were measured with immunoradiometric kits (BioSource 
Company Europe SA). HOMA IR was calculated using the 
formula: [fasting insulin level (μIU/mL) x fasting glucose 
level (mmol/L)]/22.5. Serum FGF23 levels were measured 
in a fasting blood sample by Human Intact FGF23 Enzyme-
Linked ImmunoSorbent Assay (Immunotopics Inc. USA), 
a two affinity purified goat polyclonal antibodies to detect 
epitopes with the amino-terminal and the carboxyterminal 
portions of FGF23. Serum FGF19 levels were measured in 
a fasting blood sample by Human FGF19 Enzyme-Linked 
Immuno Sorbent Assay (ELISA) (BioVendor – Laboratorni 
medicina a.s., Czech Republic).
Ultrasonography was performed using Philips EnVisor 
unit with an 3.5 MHz scanhead.
Statistical analysis. To compare two sets of data, the t-Student 
test was employed for independent samples, and in the case of 
absence of normal data distribution – the two-sided Mann-
Whitney U test was used. The level of significance was set 
at p<0.05. Calculations were performed using STATISTICA 
10.0 PL.
The study was conducted according to the principles 
expressed in the Declaration of Helsinki, and approved by 
the Jagiellonian University Bioethical Committee (Decision 
No. KBET/38/B/2008). All participants and their parents 
signed informed consent.
RESULTS
Mean BMI value in the whole group was 32.5 kg/m2 [SD 4.85]; 
mean BMI SDS – 4.65 [SD 1.67]. There was no significant 
difference concerning BMI values in patients with normal 
and low 25OHD levels – 30.5 kg/m2 [SD 4.02] vs 33.8 kg/m2 
[SD 5.12], and also BMI SDS values 4.07 [SD 1.3] vs 5.03 [SD 
1.8] respectively (Table 1).
The mean 25OHD level was 19.78 ng/mL (95%CI 15.9–
23.6). Hypovitaminosis D was recognized in 18 patients (60%; 
10 girls and 8 boys). The vitamin D deficient group presented 
with significantly higher values of diastolic blood pressure 
(125.9 vs. 115 mmHg; p=0.04), uric acid level (384.7 umol/L 
vs. 301.5 umol/L; p=0.01), and lower phosphorus level (1.4 
vs. 1.65 mmol/L; p=0.04). In patients with hypovitaminosis 
D mean values of: HOMA IR (4.5 vs. 3.8; p=0.66), ALT (34.8 
vs. 29.3 IU/L; p=0.5) and GGT (27.1 vs. 18 IU/L; p=0.9), 
were higher, but the differences were not significant. Further 
analysis showed lower, mean FGF23 and FGF19 levels (6.08 
vs.7.11; p=0.47; 128.1 vs. 150; p=0.39, respectively), but the 
differences were not significant. Detail comparison of the 
mean values of the selected biochemical parameters and 
blood pressure are shown in Table 1. More than 44% (8 
of 18) of patients with hypovitaminosis D presented with 
arterial hypertension, while only one patient with normal 
vitamin D level had elevated SBP. Liver steatosis features in 
the ultrasound examination and was present in over 44% (8 
of 18) of the patients with low, and in 25% (3 of 12) of the 
patients with normal vitamin D level.
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Table 1. Comparison of selected parameters in the metabolic assessment 











Age [years] 13.7 (1.25) 12.6 (1.86) 0.09
BMI SDS 5.03 (1.8) 4.07 (1.3) 0.16
SBP [mmHg] 125.9 (11.1) 115 (15) 0.07
DBP [mmHg] 78.6 (11.5) 69 (10.1) 0.04*
fasting glucose [mmol/L] 4.56 (0.48) 4.57 (0.57) 0.21
fasting insulin [IU/L] 21.9 (9.9) 18.1 (5.1) 0.5
HOMA IR 4.5 (2.3) 3.8 (1.1) 0.66
Total cholesterol [mmol/L] 4.32 (0.8) 4.7 (0.9) 0.37
LDLc [mmol/L] 2.6 (0.7) 2.9 (0.9) 0.34
HDLc [mmol/L] 1.1 (0.2) 1.2 (0.4) 0.98
Triglicerydes [mmol/L] 1.3 (0.54) 1.5 (0.64) 0.4
Uric acid [umol/L] 384.7 (66.8) 301.5 (80.7) 0.01*
AST [IU/L] 26.7 (8.6) 25.2 (5.1) 0.88
ALT [IU/L] 34.8 (19.7) 29.3 (5.1) 0.5
GGT [IU/L] 27.1 (2.8) 18 (5.3) 0.9
Ca [mmol/L] 2.43 (0.14) 2.47 (0.07) 0.35
P [mmol/L] 1.4 (0.25) 1.65 (0.11) 0.04*
FGF23 [pg/mL] 6.08 (2.83) 7.11 (2.88) 0.47
FGF19[pg/mL] 128.1 (65) 150 (15) 0.39
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DISCUSSION
Vitamin D deficiency, defined as serum concentration 
less than 20 ng/mL, is one of the most common nutrition-
responsive medical conditions worldwide [1, 2, 3]. However, 
although the association between hypovitaminosis D and 
obesity is well-established, there is still uncertainty which 
one is the cause, and which one is a consequence, and what 
the health consequences of lower concentrations of vitamin 
D might be. In the literature, the suggested mechanisms 
associated with obesity include: low calcium and vitamin D 
intake, less skin exposure to the sun due to reduced outdoor 
activity, reduced activation and/or increased catabolism 
than non-obese individuals, and sequestration of 25OHD 
in adipose tissue [3]. In children and adolescents who 
are overweight or obese it affects approximately 60% in 
comparison to 20% of non-obese subjects [1, 2, 3]. However, 
an inverse correlation between BMI, fat tissue content and 
vitamin D levels had been proved in many studies, and 
a recently published metaanalysis of 21 adult cohorts (up 
to 42,024 participants) revealed  that higher BMI lead to 
lower vitamin D level; but in contradiction, low vitamin 
D level does not contribute to the increase in the BMI [3]. 
These results confirm that hypovitaminosis D is rather a 
consequence, not a cause of obesity. Epidemiological-
pooled analysis of prospective observational studies of 
diverse populations demonstrates that hypovitaminosis D 
is associated with a slight risk of cardiovascular events [4, 
5, 6, 7]. The decrease of the vitamin D level has also been 
associated with higher blood pressure levels, as already shown 
in many prospective studies, as well as meta-analyses of 
observational studies [5, 6]. The results of the presented 
study confirm that both systolic and diastolic blood pressure 
in patients with hypovitaminosis D were higher, and for 
the diastolic blood pressure the difference was significant 
(125.9 vs. 115 mmHg; p=0.04). Moreover, the incidence of 
arterial hypertension among obese patients with vitamin D 
deficiency was higher than in peers with normal vitamin D 
level (44% vs. 8.3%). Low vitamin D level was also associated 
with an elevated uric acid concentration level. An association 
between vitamin D deficiency and hyperuricemia in obese 
adolescents has not been reported; however, a significant 
association between vitamin D insufficiency and elevated 
uric acid was recently found in postmenopausal women [8]. 
This novel observation seems to be particularly interesting 
since it had been proved that an elevated uric acid level is a 
significant and independent predictor of the development of 
the arterial hypertension, especially in young individuals, 
and metabolic syndrome in the future [9, 10]. These findings 
may suggest that low vitamin D level is not only one of 
the complications of the obesity, but it can be involved in 
the development of other metabolic complications. The 
relationship between low vitamin D and elevated uric acid, 
and subsequent cardiovascular complications, is currently the 
subject of many studies. The results of the studies published 
to date allow only speculation about the potential mechanism 
and need confirmation by the future investigations. It is 
suggested that vitamin D deficiency or decreased bioactivity 
can activate parathyroids to induce the release of parathyroid 
hormone (PTH). That, in turn, is considered to raise the uric 
acid level, but details of this mechanism remain unknown [9, 
10, 11]. It is suspected that elevation of the uric acid might be 
associated with the fluctuations of the fibroblast growth factor 
23 (FGF23) level [12, 13, 14]. FGF23 is a protein synthesized 
by osteocytes that has been described as having a key role 
in the ‘bone-kidney-parathyroid’ axis and the regulation 
of phosphate-calcium-PTH and 1.25(OH)D metabolism. 
Recent studies have pointed to the potential role of the FGF23 
in the development of insulin resistance and its metabolic 
consequences. Previous research by the authos of the current 
has shown that FGF23 may play a key role in the early phase 
of decreased insulin sensitivity in obese adolescents [15, 16].
The results of the presented study show,that in young 
patients with obesity and hypovitaminosis D, without 
clinical signs or symptoms of kidney disease, the FGF23 
levels were lower in comparison to individuals with normal 
25OHD levels; however, the difference was not statistically 
significant. Interestingly, the group with low vitamin D 
level and lower FGF23 level presented with significantly 
higher concentration levels of uric acid. This observation 
does not confirm the results of the previously mentioned 
study performed in pediatric patients with chronic kidney 
disease, and preserved kidney function [13], and points to 
a different and more complex mechanisms in adolescents 
with obesity. In obese adolescents, a low vitamin D level 
may slightly increase PTH which, in turn, can activate 1 
alpha-hydroxylase and subsequently increase the 1,25OHD 
level, which t may be a potential cause of the further decrease 
of the 25OHD level, leading to a vicious circle. Moreover, a 
moderate rise of the PTH level may decrease the phosphorus 
level, which is associated with the slight decrease of the 
FGF23 level, as shown in previous studies conducted in 
populations with normal kidney function [17].
The results of the presented study show higher, but 
not significant, values of the HOMA IR in patients with 
hypovitaminosis D (4.5 vs. 3.8, p=0.66). However, some 
larger studies confirmed the relationship between vitamin 
D deficiency and insulin resistance [19, 20]. Since FGF23 
is strongly involved in calcium-phosphorus-vitamin D 
metabolic pathways, it is reasonable to suspect that its 
contribution to the development of insulin resistance may 
be related to vitamin D deficiency, which is also considered 
an insulin resistance risk factor. Moreover, recent studies 
conducted on mice indicate that insulin signaling, or fat 
metabolism disturbances in the genetically ablated FGF23 
are mediated by vitamin D [19, 20, 21]. Some studies have 
pointed to the presence of low FGF23 levels in vitamin D 
deficiency; but this was not confirmed in larger groups [22]. 
These insights indicate the potential contribution of vitamin 
D to the development of insulin resistance in a novel way. 
The presented study is the first attempt to assess a possible 
relationship between FGF23 and vitamin D status in obese 
adolescents.
Another interesting observation, although also not 
statistically significant, is the elevation of liver enzymes levels, 
especially ALT and GGT, in patients with hypovitaminosis D 
(34.8 vs. 29.3 IU/L; p=0.5; 27.1 vs. 18 IU/; p=0.9 respectively). 
The ultrasound revealed liver steatosis in 44.4% of the patients 
with low, and in 25% with normal vitamin D levels. That 
confirms the results of the meta-analysis published recently 
by Eliades et. al., that revealed significantly decreased serum 
25OHD concentrations in patients with non-alcoholic fatty 
liver disease (NAFLD), suggesting that vitamin D may play 
a role in the development of this condition [21]. On the other 
side, as native vitamin D is converted to 25OHD in the liver, 
it remains controversial whether low 25OHD level is a cause 
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or a consequence of liver function impairment. Nevertheless, 
additional analysis performed in our study showed lower 
concentration level of the fibroblast growth factor 19 
(FGF19) in patients with hypovitaminosis D. Fibroblast 
growth factor 19 (FGF19) is a hormone released from the 
small intestine; recently, it has emerged as an endocrine 
regulator of glucose and lipid metabolism. The results of the 
presented study, although not statistically significant, need 
particular attention, since a decrease in fasting FGF19 is an 
independent risk factor for the development of NAFLD in 
obese adolescents [23, 24, 25]. Its relationship to vitamin D 
deficiency needs further investigation.
Although the group investigated in the presented study 
was relatively small, the very interesting and promising 
preliminary results obtained indicate the possible 
contribution of vitamin D deficiency in the development of 
metabolic obesity complications. The mechanisms of such 
contribution need further investigation.
CONCLUSIONS
Hypovitaminosis D in obese adolescents is associated with 
a higher prevalence of arterial hypertension, liver steatosis, 
elevated serum uric acid and low phosphorus levels. The 
potential contribution of the fibroblast growth factor 23 
and fibroblast growth factor 19 in the development of these 
complications needs further investigation.
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